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Stephen J. Chanock,8 and Nilanjan Chatterjee1,*
Pooling genome-wide association studies (GWASs) increases power but also poses methodological challenges because studies are often
heterogeneous. For example, combining GWASs of related but distinct traits can provide promising directions for the discovery of loci
with small but common pleiotropic effects. Classical approaches for meta-analysis or pooled analysis, however, might not be suitable for
such analysis because individual variants are likely to be associated with only a subset of the traits or might demonstrate effects in
different directions. We propose a method that exhaustively explores subsets of studies for the presence of true association signals
that are in either the same direction or possibly opposite directions. An efficient approximation is used for rapid evaluation of p values.
We present two illustrative applications, one for a meta-analysis of separate case-control studies of six distinct cancers and another for
pooled analysis of a case-control study of glioma, a class of brain tumors that contains heterogeneous subtypes. Both the applications
and additional simulation studies demonstrate that the proposed methods offer improved power and more interpretable results when
compared to traditional methods for the analysis of heterogeneous traits. The proposed framework has applications beyond genetic asso-
ciation studies.Introduction
Meta-analysis offers a powerful tool for combining distinct
genome-wide association studies (GWASs). Recent
reports1,2 have yielded additional discoveries when the
underlying studies were relatively homogeneous, but
major methodological challenges have emerged as the field
moves toward combining studies from distinctly different
populations and study designs. Most importantly, a new
approach is needed for combining existing GWASs of
distinct but putatively related traits that can provide
insights into pleiotropic effects2–6 of known susceptibility
loci and aid the discovery of novel susceptibility regions
affecting multiple traits. Although standard approaches
to meta-analysis work well when GWASs are combined so
that the average effect of a SNP marker on a single trait
can be measured, these methods are not optimal for the
analysis of distinct traits for which the effect of individual
susceptibility loci manifests only in a specific subset or in
different directions for different traits.
Similar statistical issues arise in the analysis of case-
control studies in which cases comprise distinct subtypes
with heterogeneous genetic architecture. For example, in
recent studies of select cancers,7–9 histologically distinct
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The Amtibilities. Accordingly, an overall ‘‘pooled’’ case-control
analysis reduces the power for detecting susceptibility
loci specific to certain subtypes.10 Restriction of the anal-
ysis to individual subtypes improves the power for detect-
ing specific associations but can lose the opportunity for
examining how loci associate withmore than one subtype.
The tradeoff between combining and separating (‘‘lump-
ing’’ versus ‘‘splitting’’) attains higher specificity at the
cost of a reduction in the sample size. An agnostic
approach that preserves the comprehensive perspective
with the likely specificity of effects would be better.
In this report, we offer an agnostic approach that gener-
alizes standard fixed-effects meta-analysis by allowing
some subset of the studies to have no effect. The method
explores all possible subsets of ‘‘non-null’’ studies to iden-
tify the strongest association signal and then evaluates
the significance of the signal while accounting for multiple
tests required by the subset search. We use modern statis-
tical theory for tail-probability approximation to develop
a multiple-testing adjustment procedure that can effi-
ciently account for correlation among different test statis-
tics without resorting to computationally expensive
resampling techniques. We constructed a one-sided
version of this method by limiting the space of hypotheses
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studies have effects in the same direction. We further
developed a two-sided version of the method to allow
non-null studies to have effects in opposite directions.
We also provide a more general formulation of the meth-
odology that allows powerful pooled analysis in the
context of a single case-control study in which cases can
consist of distinct disease subtypes. This permits both
case-control and case-case comparisons (among subsets
of disease subtypes) to detect the strongest association
signals.
We present simulation studies to explore the power of
the proposed method in the presence of heterogeneity.
The results indicate that the proposed method gains
substantial power—sometimes approaching between
100% and 500%—over some of the alternatives. The
method also performs well in distinguishing the subsets
of associated and unassociated traits for a specific variant.
Two illustrative applications of the method are shown.
In the first, we examined secondary effects of established
cancer susceptibility SNPs by using summary results of
GWASs of six distinct cancers involving a total of 21,473
cases and 25,891 controls. The analysis identified a number
of known secondary effects as well as a number of prom-
ising novel secondary effects. In another application, we
analyzed seven known susceptibility SNPs for glioma
(MIM 137800), a form of brain tumor, by using new
GWAS data from 1,856 glioma cases and 4,955 controls
from the GliomaScan Consortium. Compared with stan-
dard case-control analysis, the proposed method, which
accounts for subtype heterogeneity, produced much
stronger evidence of replication for two of the SNPs
(p values decreased by 100- and 10,000-fold, respectively).
We conclude the paper by considering further improve-
ments of the method that could use restricted and/or
weighted subset searches in order to explicitly incorporate
prior plausibility.Material and Methods
Subset-Based Meta-Analysis
We describe themethods by assuming that summary-level data are
available from individual studies (of possibly heterogeneous traits)
that participate in the meta-analysis. Let ðbk; skÞ; k ¼ 1;.;K
denote the estimates of regression parameter and its standard error
for a given SNP from each of K different studies. In standard fixed-
effect meta-analysis,11 the association for the SNP is tested on the
basis of a weighted combination of the Z statistics, Zk ¼ bk=sk, of
the form Zmeta ¼
PK
k¼1wkZk, in which wk is chosen so that
VarðZÞ ¼PKk¼1w2k ¼ 1. Under the assumption of a fixed effect of
the SNP across all studies, the optimal weights are given by
wk ¼ ð1=skÞ=

1
. ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃPK
k¼11=s
2
k
q 
, which is known to produce a result
that is asymptotically equivalent to that of a pooled analysis of the
studies.
Zmeta ¼
PK
k¼1
Zk=skﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1=s2k
p822 The American Journal of Human Genetics 90, 821–835, May 4, 2If covariate adjustments are similar across studies, then
skf1=
ﬃﬃﬃﬃﬃ
nk
p
, where nk is the sample size for the k
th study, and
thus, simple weights of the form wk ¼ ﬃﬃﬃﬃﬃpkp , in which
pk ¼ nk=
PK
k¼1nk, are close to optimal.
12 For case-control studies
with unequal numbers of cases and controls, such optimal weights
could be defined in terms of an ‘‘effective sample size,’’ which is
the harmonic mean of the number of cases and controls. If there
are shared subjects among studies, then Zmeta should be appropri-
ately standardized so that the covariance between Z statistics
across studies (see below) can be accounted for.
For the subset-based meta-analysis, we propose evaluating the
evidence of the association for a SNP for any given subset S of
the studies on the basis of the Z statistic
ZðSÞ ¼
X
k˛S
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pkðSÞ
p
Zk;
in which pðSÞ ¼ nk=
P
k˛Snk denotes the sample size for the k
th
study relative to the total sample size for the given subset S.
More generally, the weights for the subset-based meta-analysis
can be taken proportionally to 1=sk as discussed above.We propose
that the overall evidence for the association of the SNP be evalu-
ated on the basis of
Zmaxmeta ¼ maxS˛S jZðSÞ j ;
i.e., with the use of themaximum (in absolute value) of the subset-
specific Z statistics over the class S of all possible 2K  1 subsets of
the K studies. When K is large, the number of possible subsets
grows exponentially. The computation of Zmaxmeta, however,
can be done rapidly given that the evaluation of each ZðSÞ simply
involves taking a different weighted sum of precomputed
quantities.
Under the null hypothesis of no association for the SNP in any
of the individual studies, the vector of test statistics ZðSÞ for
different values of S should follow a multivariate normal distribu-
tion with a mean of zero and unit variance for each component
and with covariance between a pair of subsets A and B of the form
CovfZðAÞ;ZðBÞg ¼
X
k˛A;B
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pkðAÞ
p ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pkðBÞ
p
þ
X
l˛AnB
X
m˛BnA
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
plðAÞ
p ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pmðBÞ
p
CovðZl;ZmÞ:
If all of the individual studies are independent, i.e., if they don’t
have any shared subjects between them, then the second term in
the above sum disappears. If the individual studies are not inde-
pendent, it is possible to obtain analytic expressions for covari-
ance terms on the basis of information on shared subjects.13 Later
in this section, we provide a general formula for such covariance
terms for case-control studies when cases or/and controls are
shared between certain studies.
Once the multivariate distribution of subset-specific Z statistics
is characterized as above, the next task is to obtain the distribution
of the maximum. In this report, we exploit some recent theory for
tail approximations for multivariate distributions to obtain
analytic but sharp upper bounds for the p values of the proposed
test statistics. The discrete local maxima (DLM) method14 gives
an accurate way of estimating tail probabilities of a test statistic
(e.g., a Z score) that is maximized over a grid. It takes advantage
of the local correlation structure of the statistics over neighboring
grid points. In our application, the grid points represent different
subsets, and two subsets are defined as neighbors if one can be ob-
tained from the other when a single study is added or dropped.012
The DLM-based approximate p value for the one-sided test
with an observed test statistic Zmaxmeta ¼ T is given by (see
Appendix B)
PDLM ¼
X
s˛S
ZN
T
2 prðneighboring subsets have absolute Z score
< z jZs ¼ zÞfðzÞdz;
where fð:Þ denotes the standard normal density and S indexes all
possible subsets involved in the maximum. Further invoking the
so-called ‘‘separability’’ assumption,14 which is essentially that
the neighboring subsets are conditionally independent condi-
tional given the current subset, the above p value can be approxi-
mated by
~PDLM ¼
X
s˛S
ZN
T
2
YK
k¼1
prð jZs5k j< z jZs ¼ zÞfðzÞdz:
Separability in this context can be justified by the conservative-
ness of the above approximation (Appendix D). The conditional
probabilities in the last expression can be evaluated with a univar-
iate conditional normal distribution in which covariances
between subsets are calculated on the basis of formulae given in
the next section. For more details on the derivation and discussion
of the assumptions made, see Appendix B. Numerical investiga-
tions with the use of simulation studies demonstrate that the
above procedure can maintain desired type-I error rates for all of
the different subset-based methods considered (Tables S4 and S5,
available online).Two-Sided Tests
To construct a powerful two-sided statistic for the detection
of effects in opposite directions, we search for subsets of studies
that show the strongest association signals separately in positive
and negative directions to obtain Zmax;þ and Zmax;, respectively.
We then aim to combine the two statistics by using a chi-square
method. To circumvent the problem of dealing with a complex
negative correlation between jZmax;þj and jZmax;j, we first
evaluate the p values, namely ~P
þ
DLM and
~P

DLM , of the two tests
by conditioning on the observed signs of the Z statistics of the
individual studies. These conditional p values, which are obtained
by a minor modification of the aforementioned DLM method
(see Appendix B), can be shown to be distributed independently
of one another under the assumption that the individual studies
are independent. Thus, they provide a convenient way of
combining the association signals with the use of Fisher’s
method,15 i.e.,
Z
ð2Þ
maxmeta ¼ 2

log ~P
þ
DLM þ log ~P

DLM

and
~P
ð2Þ
DLM ¼ P

c24 > Z
ð2Þ
maxmeta

:
When all the observed association signals are on one side
(say positive), we use Z
ð2Þ
maxmeta ¼ 2 log ~P
þ
DLM and
~P
ð2Þ
DLM ¼ ~P
þ
DLM .Analysis of Case-Control Studies with Heterogeneous
Disease Subtypes
We adapt the proposed method to account for heterogeneity
among disease subtypes within a single case-control study. We
consider two types of subset-based analysis. In one (‘‘case-
control’’), we compare each subset of the disease subtypes withThe Amthe fixed control group. In another (‘‘case-complement’’), we
compare each subset of the disease subtypes with its complemen-
tary subset that includes the common control group as well as the
other case subtypes. The latter approach is potentially more
powerful given that each subset of cases is being compared with
a larger pool of ‘‘controls.’’ For either of these analyses, it is possible
to characterize the multivariate distribution of Z statistics for all
the different subset-based tests, and one can therefore use the
procedure described above to assess the significance of the
maxima of these subset-based tests. If ZðAÞ and ZðBÞ denote
the Z statistics for the association test for a SNP from case-control
studies A and B with an arbitrary amount of overlap between
subjects, then, under the null hypothesis of no association and
the assumption that there is no covariate adjustment, the correla-
tion between the statistics is given by
CorrfZðAÞ;ZðBÞg ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n
ð1Þ
A n
ð0Þ
A
NA
s ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n
ð1Þ
B n
ð0Þ
B
NB
s "
n
ð11Þ
AB
n
ð1Þ
A n
ð1Þ
B
 n
ð10Þ
AB
n
ð1Þ
A n
ð0Þ
B
 n
ð01Þ
AB
n
ð0Þ
A n
ð1Þ
B
þ n
ð00Þ
AB
n
ð0Þ
A n
ð0Þ
B
#
;
where n
ð1Þ
A , n
ð0Þ
A , and NA are the number of cases, controls, and
subjects, respectively, in study A (and in study B with corre-
sponding notation) and n
ðijÞ
AB denotes the number of subjects
with different phenotype categories ði; jÞ˛ð0;1Þ who overlap
between studies A and B. For example, n
ð00Þ
AB denotes the number
of shared controls between studies A and B, and n
ð10Þ
AB denotes
the number of individuals who are treated as cases in study A
but as controls in study B. Similar analytic expressions for
covariances have been derived previously for special cases.13,16
Once the correlation structure between the Z scores for case-
control or case-complement analysis of disease subtypes is ob-
tained as above, the one-sided-subset search procedure is used,
and p values are approximated with the DLM procedure (see
Appendix C).Restricted and Weighted Subset Search
The proposed testing framework can allow restricted and/or
weighted subset searches that could incorporate prior plausibility
of models. For the analysis of ordered disease subtypes, for
example, one might consider subset searches by cumulatively
collapsing the subtypes in backward and forward directions.
Such restricted analysis can not only improve the power of the
detection of overall association by reducing the number of tests
compared to an agnostic search but also lead to findings that are
easier to interpret. The DLM procedure used for the evaluation
of p values extends to such restricted searches with appropriate
modifications for the ‘‘class of all subsets’’ and the definition of
‘‘neighboring subsets.’’
In certain applications, one can incorporate prior knowledge,
such as the degree of relatedness among traits, in the proposed
analysis by using a weighted hypothesis-testing framework.17,18
The agnostic subset-based method can be thought of as testing
each subset for association while spending equal type I error for
all subsets. If certain hypotheses (subsets) are more likely to be
true (associated) on the basis of prior knowledge, a natural idea
is to spend type I error differentially so that more plausible subsets
can be tested with the use of more liberal thresholds. More
formally, one can achieve this by defining a weighted test statistic
for each subset aserican Journal of Human Genetics 90, 821–835, May 4, 2012 823
Table 1. Performance of the Subset-Based Test for Detection of
the Truly Associated Subset of TraitsTs ¼ ps
ws
¼ 2½1 Fð jZs j Þ
ws
;(K, T1, T2)
Sensitivity (True
Positive Probability)
Specificity (True
Negative Probability)
One-Sided Two-Sided One-Sided Two-Sided
5 traits: 100% positive
(5, 1, 0) 0.920 0.986 0.835 0.500
(5, 2, 0) 0.943 0.943 0.886 0.505
(5, 3, 0) 0.934 0.935 0.921 0.477
(5, 4, 0) 0.924 0.925 0.926 0.412
5 traits: 75% positive
(5, 1, 1) 0.502 0.982 0.883 0.721where, for each subset s, jZsj is the subset-specific meta-analysis
test statistic discussed earlier, ps is the associated nominal p value,
andws is a prespecified weight. Now, an overall test statistic for de-
tecting the strongest signal over different subsets and the corre-
sponding p value can be defined as
T ðwÞmin ¼ mins˛STs ¼ Ts0 and pðwÞ ¼ pr

T
ðwÞ
min < Ts0 jH0

;
where s0 ¼ argminSTs. With the use of the definitions above, the
multivariate distribution of the Ts’s can be rewritten in terms of
the associated Z scores, which have amultivariate normal distribu-
tion. Therefore, the p value pðwÞ can again be approximated with
an appropriate modification of the DLM procedure.(5, 2, 1) 0.621 0.971 0.906 0.745
(5, 3, 1) 0.676 0.950 0.918 0.782
10 traits: 100% positive
(10, 2, 0) 0.942 0.953 0.879 0.563
(10, 3, 0) 0.941 0.944 0.893 0.579
(10, 4, 0) 0.932 0.932 0.914 0.587
(10, 5, 0) 0.926 0.927 0.923 0.573
(10, 6, 0) 0.927 0.927 0.922 0.557
(10, 7, 0) 0.922 0.924 0.933 0.522
10 traits: 75% positive
(10, 1, 1) 0.500 0.978 0.855 0.675
(10, 2, 1) 0.621 0.973 0.877 0.698
(10, 3, 1) 0.672 0.955 0.901 0.739
(10, 3, 2) 0.566 0.934 0.907 0.778
(10, 4, 2) 0.616 0.924 0.915 0.801
(10, 5, 2) 0.656 0.933 0.927 0.825
In each simulation, a total of K ¼ 5 or K ¼ 10 distinct traits are analyzed (each
trait has 2,000 cases and 2,000 controls). A variant of MAF ¼ 0.3 is assumed to
be associated with a subset of size T (<K) of the traits with an odds ratio of 1.15
(see Table S1 for results under heterogeneity of odds ratios). The ‘‘100% posi-
tive’’ sections assume that all of the associations are in the same direction, and
the ‘‘75% positive’’ sections assume that 75% of the associations are positive
and 25% are negative. The two measures of performance that are shown are
(1) sensitivity (the average proportion of associated traits detected) and (2)
specificity (the average proportion of null traits discarded). The following
abbreviations are used: K, total number of traits analyzed (5 or 10); T1, number
of traits that are truly associated in the positive direction; and T2, number of
traits that are truly associated in the negative direction.Simulation Studies
We conducted simulation studies to evaluate the type I error and
power of the various statistics discussed. In each case-control
simulation, the genotype frequencies in the underlying popula-
tion were assumed to be under a Hardy-Weinberg equilibrium
with a minor allele frequency (MAF) of 0.3. We then induced
the genotype frequencies for the cases and controls by setting
a disease prevalence of 1% and a logistic linear disease model of
the form
logit prðD ¼ 1 jG ¼ gÞ ¼ aþ bg;
where b denotes the log-OR (odds ratio) association parameter.
We considered two different study settings. In the first (Table 1
and Figure 1), we considered a total of K ¼ 5 or K ¼ 10 indepen-
dent case-control studies of possibly heterogeneous traits (each
study had 2,000 cases and 2,000 controls). For each K, we
assumed that a given SNP is associated with the outcome only
for a fraction p (up to rounding) of the studies with p ¼ 1/5, 2/
5, 3/5, 4/5 or 1. Among studies that contained true associations,
the number of studies, T1, with a positive effect of the SNP was set
such that a ¼ T1/K is either 1 (i.e., all effects are in the same direc-
tion) or 3/4 (i.e., some effects are in opposite directions) up to
rounding. In the main simulations, we assumed that the magni-
tude of the effects of a SNP on the associated outcomes was
constant (OR ¼ 1.15), and we obtained the effects in opposite
directions by simply reversing the sign of the log-OR coefficients.
In additional simulations (Table S1 and Figure S1), we allowed
heterogeneity in the effect of a SNP on the associated outcomes.
In this setting, we allowed the genotype OR among positively
associated traits to vary approximately in the range of 1.05 to
1.25 (a mean of 1.15).
In the second setting (Figure 2), we considered a single case-
control study with K¼ 7 distinct case groups (representing disease
subtypes). We assumed that the study included a total of 14,000
cases (2,000 subjects in each case group) and a shared control
group that contained either N0 ¼ 14,000 or 3,000 subjects. We al-
lowed the number of disease subtypes, T1, that are truly associated
with a SNP to vary. For each case type, the genotype OR for a SNP
was fixed at 1 for unassociated subtypes and at 1.15 for associated
subtypes. For both these settings, the type I error (Tables S4 and
S5) was estimated at levels 0.05, 0.01, and 0.001 with 1,000,
5,000 and 50,000 simulation replicates, respectively. Power was
estimated for levels 0.001 and level 107 (Figure S3) with 500
replicates.824 The American Journal of Human Genetics 90, 821–835, May 4, 2Results
We conducted simulation studies to investigate the power
of alternative methods to detect a susceptibility SNP by
combining signals across multiple studies of heteroge-
neous traits. In each simulation, it is assumed that only
a subset of the studies (traits) contains true signals
(Figure 1). When all of the studies that contain true associ-
ation signals (i.e., non-null studies) have effects in the
same direction (Figure 1, upper panel) and when the
number of true studies containing the signal is small012
Figure 1. Simulation-Based Power comparison of Alternative Methods for Detecting an Overall Association
In each simulation, it is assumed that a total of five or ten distinct traits are analyzed (for each trait, there are 2,000 cases and 2,000
controls). A variant with a MAF ¼ 0.3 is assumed to be associated with a subset of the traits (the number of such traits is shown on
the x axis) and has a fixed OR of 1.15 (see Figure S1 for results under heterogeneity of ORs). The upper panels assume that all of the asso-
ciations are in the same (positive) direction, and the lower panels assume that 75% of the associations are positive and 25% are negative.
In addition to the two-sided (green line) and one-sided (orange line) subset-based tests, power curves are also shown for the overall meta-
analysis (blue line), Fisher’s combined p value method (a multiple-degree-of-freedom [df] chi-square test) (maroon line), and a ‘‘gold-
standard’’ test (black line) that assumes that the subset of non-null traits that are truly associated with the given SNP are known a priori.
All powers are shown at an alpha level of 0.001.relative to the total number of studies included in the anal-
ysis, we observe that substantial power is gained by both
the one-sided and two-sided tests as well as the multiple-
degree-of-freedom (df) chi-square test (Fisher’s combined
p value method) when they are compared with the stan-
dard fixed-effect meta-analysis method. For example, in
the simulation setting in which ten studies are included
in an analysis but only three contain true association
signals, the power for detection of the SNP was 26.8% for
the standard meta-analysis and was 70.4% and 63.6% for
our proposed one-sided and two-sided tests, respectively.
In this scenario, it is noteworthy that the one-sided test
gained significant power over both the proposed two-sided
and multiple-df chi-square tests. When non-null studies
contained association signals in opposite directions, the
power loss was more substantial for standardmeta-analysis
than for the alternatives (Figure 1, lower panel). In this
setting, we observe that the proposed two-sided test and
the multiple-df chi-square test perform similarly, and
both can provide substantial gain in power over the one-The Amsided test by combining association signals from opposite
directions. Qualitatively similar behavior was observed
for all methods when we allowed for a significant amount
of heterogeneity among the ORs within non-null studies
in the simulations (Figure S1).
It is instructive to compare the power of the proposed
tests with that of the ‘‘gold-standard’’ test, namely one
that assumes the true subset of non-null studies to be
known a priori. It is evident that there is a significant
loss of power for the proposed tests as a result of
a multiple-testing penalty associated with comprehensive
subset searches. The magnitude of such loss depends on
the total number of studies included in the analysis given
that the number of subsets to be explored increases expo-
nentially with the number of studies. For example, in the
setting of Figure 1, where only three studies contain the
true effect, the power of the one-sided test is either
82.8% or 70.4% depending upon whether the studies are
evaluated against a total of 5 or 10 studies, respectively.
When the correlation between different subset analyses iserican Journal of Human Genetics 90, 821–835, May 4, 2012 825
Figure 2. Simulation-Based Power Comparison
of Alternative Methods in the Analysis of a Case-
Control Study with Heterogeneous Disease
Subtypes
Each simulation includes 14,000 cases equally
distributed over seven subtypes. The left and
right panels correspond to designs with 14,000
and 3,000 controls, respectively. A variant with
a MAF of 0.3 is assumed to be associated with
a subset of the subtypes (the number of such
subtypes is shown on the x axis) and have a fixed
OR of 1.15. The power curves for two alternative
subset-based tests, ‘‘case-control’’ (orange line)
and ‘‘case-complement’’ (green line), are shown
along with those for an overall case-control anal-
ysis (blue line) and a ‘‘gold-standard’’ (black line)
case-complement test that assumes that the
subset of associated subtypes is known a priori.
All powers are shown at an alpha level of 0.001.accounted for, the penalty associated with multiple testing
is lower than that associated with a standard Bonferroni
procedure (see Figure S2), i.e., multiplication of the p value
of the maximal subset by the total number of subsets. It is
noteworthy that even after adjustment for a large number
of comparisons, the subset-based approach, relative to
standard meta-analysis, can yield a major gain in power.
We evaluate how the proposed methods perform in de-
tecting the correct subset of non-null studies (Table 1).
Regardless of the ratio of the number of null and non-
null studies, the proposedmethods can achieve high sensi-
tivity and specificity as a tool for set selection. For example,
in the setting of Table 1 inwhich five out of ten studies con-
tained true association signals in the same direction, the
proposed one-sided test had a sensitivity of 92.6%and spec-
ificity of 92.7%. In other words, the method on average
included 5 3 0.921 ¼ 4.6 of the non-null and 5 3
(10.927) ¼ 0.37 of the null studies in the detected set of
associations. The two-sided test can have higher sensitivity
in the presence of true effects in opposite directions, but it
can also have lower specificity as it attempts to identify two
distinct sets over which the risk of false positives is accumu-
lated. When we allowed for heterogeneity in ORs among
the non-null studies (Table S1), as expected on theoretical
grounds (see AppendixA), the sensitivities of bothmethods
were reduced, but the specificities remained comparable to
those in the absence of heterogeneity.
Simulation studies also illustrate that the subset-based
methods can gain power over standard approaches to the
analysis of case-control studies when the cases contain
etiologically heterogeneous subtypes (Figure 2). For
example, in the left panel of Figure 2, when a SNP is
assumed to be related to only two of seven subtypes,
then the standard case-control analysis has an estimated
power of approximately 13% for detecting the association.
In contrast, for the same setting, the power of the subset-
based analyses was >80%, which is only marginally lower
than the ‘‘gold standard’’ test, which assumes that the
correct subset is already known. The gain in power of the
subset-based analysis over the standard analysis is particu-826 The American Journal of Human Genetics 90, 821–835, May 4, 2larly remarkable given that the former requires multiple-
testing adjustment for 271 ¼ 127 comparisons. We
observe little difference in power between the alternative
‘‘case-control’’ and ‘‘case-complement’’ approaches when
the number of controls is similar to the total number of
cases in the study (Figure 2, left panel). However, in the
alternative setting (Figure 2, right panel), in which the
number of controls is significantly smaller than the total
number of cases, a substantial power advantage is observed
for the ‘‘case-complement’’ approach.
We provide a case study to illustrate the utility of the
method in the investigation of an established association
of rs2736100, a SNP in the TERT (MIM 187270)-CLPTM1L
(MIM 612585) area of chromosomal region 5p15.33, by
using data from GWASs of six different cancers that have
been reported6,9,19–22 previously (see Table S2 for details
on sample sizes). The TERT-CLPTM1L region is known to
be associated with at least seven distinct cancers,23–25 but
rs2736100 (or other strongly correlated SNPs) has been
associated with three cancers (lung adenocarcinoma,
glioblastoma [MIM 137800], and testicular germ cell
tumors [MIM 273300])7,24–27 as well as idiopathic pulmo-
nary fibrosis28 (MIM 178500) and a form of bone-
marrow-failure syndrome dyskeratosis congenita (MIM
613989).29,30 An analysis of this SNP illustrates the oper-
ating characteristics of the method both for evaluating
the overall significance of the association and for the selec-
tion of the associated subsets. A forest plot (Figure 3) shows
that the minor allele for this SNP is positively associated
with one cancer, negatively associated with some others,
and possibly has no effect on a third group. The standard
meta-analysis did not provide significant evidence for an
overall association (p ¼ 0.1432). In contrast, the one-sided
test detected the cluster of cancers of the kidney (MIM
144700) and lung (MIM 211980) to be negatively associ-
ated with the SNP (p ¼ 4.43 3 104). The two-sided search
additionally detected pancreatic cancer (MIM 260350) as
positively associated, which has been reported previ-
ously,25,31 and increased the significance of the overall
association substantially (p ¼ 1.23 3 105).012
Figure 3. Forest Plot showing the Effect of
a TERT SNP across Cancers at Six Different Sites
A two-sided subset-based test found (1) the
cluster of kidney and lung cancers to be nega-
tively associated, (2) pancreatic cancer to be posi-
tively associated, and (3) the cluster of breast,
prostate, and bladder cancers to have no associa-
tion. The p values for overall association with the
use of standard meta-analysis, one-sided, and
two-sided subset-based tests are shown along
with their respective OR estimates at the bottom
of the figure.Next, we applied our newmethod to examine secondary
effects for 89 previously reported cancer susceptibility
SNPs in other GWASs32 by using the data set described
above. Here, in the analysis of each SNP, we exclude the
primary cancer (if it was present in our data set) for which
the locus was reported originally. Our two-sided analysis
identified a total of 16 loci that showed statistically signif-
icant secondary effects at a nominal level (p < 0.05)
(Table 2). A number of SNPs that are in the TERT-CLPTM1L
region and that have known effects across multiple cancers
achieved strong statistical significance (false discovery rate
[FDR]-adjusted p value < 0.05). The region generally
showed consistent secondary effects for pancreatic cancer
in one direction and for bladder (MIM 109800), lung,
and kidney cancers in the opposite direction. In the 8q24
region (rs6983267), a SNP that has previously been identi-
fied in GWASs of colon33,34 and prostate35 (MIM 176807)
cancers showed modest secondary effect for breast cancer
(MIM 114480) in one direction and for lung, bladder,
kidney, and pancreatic cancers in the opposite direction.
There was clear evidence of enrichment for secondary
effects of known cancer SNPs even after excluding SNPs
in the known pleiotropic regions of TERT-CLPTM1L and
8q24. A binomial enrichment test comparing the numbers
of observed and expected SNPs below a p value threshold
of 0.05 achieved strong statistical significance (p ¼ 9.6 3
105). High statistical significance (FDR-adjusted p value
< 0.05) for specific secondary effects is observed for the
non-Hodgkin-lymphoma-associated region PSORS1C1
(MIM 613525)-CDSN (MIM 602593) in kidney cancer
and for the prostate-cancer-associated SNP rs2660753 (in
chromosomal region 3p12) in kidney and breast cancers.
Other notable results, although of less significance, include
secondary effects of the regionsMSMB (MIM 157145), ABO
(MIM 110300), and HNF1B (MIM 189907), each of which
has been suggested to contribute to multiple cancers or
related traits.
Finally, we applied the proposed subtype-analysis
approach to investigate the association for seven knownThe American Journal ofglioma susceptibility loci24,36,37 by using
a new GWAS from GliomaScan, a consor-
tium of 18 studies (Table S3). There were
1,856 cases, including those of all primary
gliomas and those of a limited number ofother neuroepitheliomatous tumors (ICD-O-3 code 9380-
9480 and ICD-O-3 9490-9523), and 4,955 glioma-free
controls at the time of selection. Detailed morphology
and histology codes were requested from all cases when
available. On the basis of this information, glioma cases
were classified into six subgroups that are expected to be
more homogenous because of their histology and
behavior. These classifications were GBM (glioblastoma
[ICDO-3 9440, 9441]), HGG-AST (other high-grade astro-
cytoma [ICDO-3 9401]), LGG-AST (low-grade astrocytoma
[ICDO-3 9381, 9400, 9411, 9420, 9421, and 9424]),
OLIGO (mixed oligoastrocytoma and oligodendroglioma
[ICDO-3 9382, 9450, 9451, and 9460]), OTH (other low-
grade and high-grade glioma [ICDO-3 9383, 9390-9394,
9470-9473, 9500, 9503, 9505, and 9506]), and UNK
(glioma of unknown histology). All analyses were carried
out with individual-level data and included adjustment
for eigenvectors.
Standard case-control analysis via logistic regression
replicated association for three of the regions, TERT,
CDKN2BAS (MIM 613149), and RTEL1 (MIM 608833)-
TNFRSF6B (MIM 603361), at a genome-wide significance
level (p value < 107). Moreover, the analysis also repli-
cated the association for two other SNPs, rs4295627 (chro-
mosomal region 8q24.1) and rs2252586 (EGFR [MIM
131550] locus in chromosomal region 7p11.2), at a Bonfer-
roni-adjusted significance level of 0.05/7 ¼ 0.007. For each
of the five SNPs, the new methods that incorporated
subtype information replicated the association at a compa-
rable level of significance. However, for two additional
SNPs in the chromosomal regions 7p11.2 (EGFR) and
11q23.3 (PHLDB1 [MIM 612834]), the proposed methods
provided much stronger evidence of replication, whereas
standard analysis failed to replicate association at the
significance level of 0.05/7. For rs11979158 (EGFR region),
which showed a GBM-specific effect, the p value improved
from 1.21 3 102 for overall logistic to 5.85 3 104 and
5.10 3 104 for the subset-based case-control and case-
complement analyses, respectively. For SNP rs498872Human Genetics 90, 821–835, May 4, 2012 827
Table 2. Results from Two-Sided Analysis of 89 Established Cancer GWAS Hits Based on Data from Six Cancer Sitesa
Rank SNP
Original
Phenotype(s) MAF Chr
Gene
Neighborhood
Two-Sided
p Value
Significant Phenotype Clustersb
FDR- Adjusted
p Value
Positively
Associated
Negatively
Associated
1 rs401681 basal cell
carcinoma
0.45 5 CLPTM1L 5.99 3 108 pancreatic
cancer
bladder and
lung cancers
5.27 3 106
2 rs2736100 brain and lung
cancers
0.50 5 TERT 3.61 3 104 pancreatic
cancer
kidney cancer 1.08 3 102
3 rs6457327 non-Hodgkin
lymphoma
0.36 6 C6orf15,
PSORS1C1, CDSN
3.68 3 104 kidney cancer 1.08 3 102
4 rs2660753 prostate cancer 0.11 3 LOC285232 3.17 3 103 breast and
kidney cancers
6.97 3 102
5 rs29232 nasopharyngeal
cancer
0.36 6 GABBR1,
SUMO2P, MOG
6.22 3 103 kidney cancer 9.49 3 102
6 rs6010620 brain cancer 0.22 20 RTEL1,
TNFRSF6B
6.47 3 103 bladder cancer 9.49 3 102
7 rs10993994 prostate cancer 0.38 10 MSMB 8.62 3 103 bladder and
kidney cancers
1.08 3 101
8 rs6983267 prostate and
colorectal
cancers
0.50 8 POU5F1B 1.08 3 102 breast cancer bladder, kidney,
lung, and
pancreatic cancers
1.10 3 101
9 rs1051730 lung cancer 0.34 15 CHRNA5,
CHRNA3
1.12 3 102 bladder and
breast cancers
1.10 3 101
10 rs505922 pancreatic
cancer
0.37 9 ABO 1.31 3 102 kidney and
lung cancers
1.16 3 101
11 rs10411210 colorectal
cancer
0.12 19 RHPN2 1.74 3 102 bladder cancer 1.39 3 101
12 rs258322 melanoma 0.10 16 CDK10, SPATA2L,
LOC100128862
1.92 3 102 kidney cancer 1.41 3 101
13 rs9642880 bladder cancer 0.46 8 2.54 3 102 breast and
pancreatic
cancers
1.72 3 101
14 rs4430796 prostate cancer 0.47 17 HNF1B 4.27 3 102 lung cancer 2.51 3 101
15 rs4779584 colorectal cancer 0.22 15 SCG5, GREM1 4.63 3 102 kidney cancer 2.51 3 101
16 rs872071 chronic
lymphocytic
leukemia
0.49 6 IRF4 4.90 3 102 kidney cancer 2.51 3 101
For each SNP, the primary cancer(s) through which the SNP was originally discovered is (are) excluded, and a two-sided subset search is conducted among the
remaining cancers. SNPs significant at a nominal 5% level are shown. The following abbreviations are used: MAF, minor allele frequency; Chr, chromosome; and
FDR, false discovery rate (Benjamini-Hochberg procedure).
aData for this example were obtained from the National Cancer Institute GWASs. See Table S2 for details on sample sizes.
bThose clusters with a corresponding one-sided p value (i.e., pþ or p) less than or close to 0.05.(PHLDB1 region), which showed effects on all subtypes
other than GBM, a dramatic improvement in p value was
observed from overall logistic regression (p value ¼
0.046) to subset-based case-control (p ¼ 4.73 3 105) and
case-complement (p ¼ 6.75 3 106) analyses.Discussion
We present a flexible and powerful approach to studying
heterogeneous traits, and this approach can account for
subset-specific and bidirectional effects of individual vari-
ants. Simulation studies demonstrate the utility of the
methods both for the detection of susceptibility loci and828 The American Journal of Human Genetics 90, 821–835, May 4, 2for the identification of clusters of traits with shared
genetic architecture. An illustrative analysis of secondary
effects for known cancer SNPs via the proposed method
provides preliminary evidence that pleiotropy across a set
of complex phenotypes, such as common cancer sites,
might be more common than previously reported.38
Thus, future analyses of existing GWASs across cancer sites
will be valuable for obtaining new biological insights and
for uncovering novel susceptibility loci.
Subset-based tests that account for phenotypic heteroge-
neity have been previously proposed for linkage39 and
association40,41 analyses. A challenge for their broader
use has been that evaluating the significance of their re-
sulting test statistics can be difficult. In our approach, the012
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The Amsimple forms for the test statistics and their correlation
structure enable rapid implementation of the method for
large-scale studies and the evaluation of small p values
that are needed for achieving significance in GWASs. We
have used the DLM method to derive an analytic approxi-
mation of the p values that we have found to be both
computationally and statistically efficient. It is also easy
to implement alternative, possibly more exact methods
for evaluating p values on the basis of the general formula
we provide for the variance-covariance structure of the
underlying Gaussian field for which the proposed test
statistic is amaximum. In particular, stochastic alternatives
such as the R package mvtnorm42 and importance sam-
pling43 and parametric-bootstrap and deterministic alter-
natives such as multiple integration44 are available and
can be implemented for the use of the analytic variance-
covariance formulae we provide.
As one might expect, the greatest gain in power for our
method over standard fixed-effect meta-analysis is
observed when either a fraction of the studies contain
true associations or select studies display effects in opposite
directions (Figure 1); these two scenarios are likely for
a combined analysis of several heterogeneous traits. Also
as expected, there can be a substantial cost when a large
fraction of the studies contain association signals and
have all effects in the same direction (Figure S3). In that
scenario, which might represent the truth for meta-anal-
yses of studies of a single trait across relatively homoge-
neous populations, subset-based analyses can have lower
power than standard meta-analysis. For example, when
ten out ten studies had true effects, the power of meta-
analysis (the same as ‘‘gold standard’’) was 87.6%, whereas
that of the one-sided subset search was 67% (see Figure S3).
The magnitude of this loss increases with the total number
of studies analyzed and the associated penalty due to
multiple testing. Because the standard meta-analysis and
the subset-based approaches have complementary
strengths, it might sometimes be prudent to apply both
of them to protect against loss of power. One can split
the total type I error between the two procedures by using
a weighted hypothesis-testing framework.
Both the simulation study (Table 2) and the illustrative
example (Table 3) demonstrate that the proposed approach
also has a major advantage for the analysis of case-control
studies in the presence of subtype-specific effects for
susceptibility SNPs. In the analysis of the GliomaScan
GWAS, the proposedmethod convincingly replicated asso-
ciations for all known susceptibility SNPs, whereas stan-
dard case-control analysis provided only weak evidence
for some of the same associations. Moreover, a number
of recent independent reports,45–47 which corroborate
some of the subtype-specific effects we detected for SNPs
rs497756 (in CDKN2BAS in chromosomal region 9p21.3),
rs4295627 (in chromosomal region 8q24.1), and
rs2736100 (in TERT in chromosomal region 5p15.33),
provide additional support for the validity and utility of
the method. These results suggest that reanalysis oferican Journal of Human Genetics 90, 821–835, May 4, 2012 829
existing case-control GWASs with the use of disease
subtype information can discover additional variants. For
study designs with more cases than controls,48 we
observed that the subset-based case-complement approach
that permits both case-case and case-control comparisons
can yield substantial power over similar analysis restricted
to case-control comparisons. These results have implica-
tions for sample-size considerations for future case-control
studies with heterogeneous disease subtypes as well for
studies in which cases have been scanned in anticipation
of comparison to publicly available controls.
An alternative class of tests that can be used for meta-
analysis of heterogeneous studies is the multiple-df chi-
square tests, such as the Fisher’s combined p value
method.15 In their simplest form, these tests sum up indi-
vidual squared association-test statistics or transformed p
values over independent studies to obtain an overall
signal. Such methods have been used for meta-analysis of
linkage studies49 and have also been addressed in the
context of GWASs.50,51 Although such methods and
some other direction invariant tests52 are known to have
superior power over standardmeta-analysis in the presence
of heterogeneity, these methods might lead to difficulty of
interpretation because an overall significant association
could be driven by arbitrary patterns of effects in indi-
vidual studies. In meta-analysis of different studies of the
same trait, for example, an overall significant association
is generally not considered interesting unless the observed
effects are in the same direction.
In our main simulation studies, we have compared the
power of the proposed methods against that of a multiple-
df chi-square test for meta-analysis of independent studies
(Figure 1 and Figures S1 and S3). In additional simulations
(Figures S4 and S5), we compared our method with two
adaptiveversionsof thechi-square test,namely theadaptive
rank truncated product (ARTP)53 and adaptively weighted
(AW) statistics.54 These two versions also explore subsets
of studies for optimization of the underlying statistics. In
these comparisons, we found that, in general, the proposed
method and all chi-square-type tests can have comparable
power for the detection of an overall association in the pres-
ence of heterogeneity, although there are specific scenarios
in which one method can outperform the other. In prin-
ciple, chi-square-type tests can also be adapted to take into
account directional and ordering constraints and possibly
prior weighting for the improvement of the interpretation
of the results, but these extensions require further develop-
ments. Additional methodological developments are also
needed for the application of some of these methods for
meta-analysis of correlated studies and analysis of case-
control studies with heterogeneous disease subtypes. In
some of these methods, however, the evaluation of p values
might necessarily require expensive permutation algo-
rithms because analytic approximations similar to those
for the proposed methods might not be possible.
A recent study proposed the examination of pleiotropic
effects on the basis of the enrichment of p values reaching830 The American Journal of Human Genetics 90, 821–835, May 4, 2a specific significance threshold across multiple GWASs of
related traits.55 Such enrichment methods, although
appealing as simple screening tools, do not incorporate
the total evidence of association from individual studies.
Thus, they are likely to lose power in the presence of
studies that might contain significantly stronger or weaker
individual association signals than those imposed by
a specific p value cutoff. The subset-based approach to
meta-analysis has some similarity with a recent method56
proposed for combining association signals across multi-
variate phenotypes on the basis of weighted-sum test
statistics in which the weights for individual traits are esti-
mated first on the basis of a held-out ‘‘training’’ dataset.
The proposed method assigns 0–1 weights to individual
studies depending on their exclusion or inclusion in
a particular set and then maximizes the test statistics
over all possible such weights to obtain the best association
signal with the use of the entire dataset.
A limitation of standard meta-analysis, multiple-df tests,
and some of the other methods described above is that
they do not readily identify the true subset of traits puta-
tively associated with a specific variant. In a combined
analysis of heterogeneous traits, an important aspect of
inference is the subset identification that is needed both
for the interpretation of results and for replication efforts.
Our simulation studies indicate that the proposed method
performs well in this regard (Table 1 and Table S1). This
capability is also illustrated in an important application
in which the proposed method correctly identified signals
for additional cancers in well-established multiple-cancer
susceptibility regions, such as 8q24 and TERT-CLPTM1L
on 5p15.33 (Table 2). We further show that the proposed
method can be theoretically motivated on the basis of
a likelihood-ratio statistic and is expected to have robust
properties for set selection (See Appendix A).
Another major advantage of the proposed method over
the aforementioned alternatives is its flexibility to enable
improvement of power and interpretation by using
restricted and weighted subset searches. As noted earlier,
the one-sided test is one form of restricted search that
ensures that the overall association is driven by a cluster
of studies with effects in the same direction. Similarly, if
there is a certain ordering among the disease subtypes,
e.g., stages of a cancer or levels of diagnosis for a psychiatric
disorder, then the subset search can be easily restricted so
that the overall association is not driven by biologically
implausible patterns (see Material and Methods). The
proposed method can also take into account less restrictive
constraints, such as prior knowledge of possible clustering
of the traits, by applying continuous weights to subsets. In
studies of cancers that occur at different organ sites, for
example, a prior grouping or a similarity metric can be
defined on the basis of studies of familial aggregation, of
second cancers, and of known effects of shared biologic
pathways or common environmental exposures such as
smoking. A weighted hypothesis-testing framework (see
Material and Methods) allows the incorporation of such012
information as prior weights in such a way that the overall
type-I-error rate of the procedure does not depend on the
correctness of these weights, and yet power can be gained
when the prior information is reasonable.
In conclusion, the proposed subset-based association-
testing framework has multiple attractive features for
meta-analysis or pooled analysis of heterogeneous studies.
The method not only has robust power for the detection of
overall association but also is appealing because it leads to
readily interpretable results. We provide an analytic
approach for the approximation of p values that can be
evaluated rapidly in large-scale studies. Furthermore, the
generality and flexibility of the framework lend it potential
applicability in a wide variety of settings, such as for both
meta-analysis of heterogeneous traits and subtype analysis
for a single trait. These methods are likely to have other
applications within genomics (such as gene-environment
interaction and gene-expression studies) and, more gener-
ally, even within other contexts involving extensive
heterogeneity of effects. The methods proposed here
have been implemented in a user-friendly R statistical
package called ASSET (association analysis based on
subsets).Appendix A: Properties of Zmaxmeta—Equivalence
with Likelihood Ratio Test and Consistency as
a Variable Selector
Let bbj denote effect-size estimates obtained from indepen-
dent studies that are possibly heterogeneous, and let s2j be
the corresponding standard errors that can be assumed to
be fixed constants for the purposes of this section.
Consider the following underlying model for heteroge-
neity:
bb j  Nbgj; s2j ;gj˛f0; 1g; j ¼ 1;.K;
where gj is a binary indicator of the j
th study being ‘‘non-
null.’’ For any fixed values of the gj-s, the MLE (maximum
likelihood estimate) of b is simply given by the inverse-
variance weighted average
bb ¼
PK
j¼1
gj
bb j=s2j
PK
j¼1
gj=s
2
j
:
Because the true gj’s are not known, the likelihood needs
to be maximized with respect to b and the gj’s. The corre-
sponding LRT (likelihood ratio test) can thus be derived as
LRTðb;GÞ ¼ max

1;maxgs0
supb L
bb1; bb2;.; bbKrb¼b;G¼g	
L
bb1; bb2;.; bbKrb¼0;G¼g	


¼ exp

Z2maxmeta
2

:The AmNext, we show that under the above model, Zmaxmeta is
a consistent variable selector in the sense that in large
samples, it is guaranteed to bemaximized for the true value
of G ¼ g0 and will therefore correctly identify the subset of
studies that contain true associations. We can write
pr

argmaxgZ
bb;g	sg0	¼ pr W
gsg0
jZbb;g	 j> jZbb;g0	j	
R
X
gsg0
pr
jZbb;g	j> jZbb;g0	j:
Let bi ¼ EðbbiÞ denote the true population value of the
effect size for the ith study. We assume s2i ¼ s2=ni for
some constant s2 so that the standard error for each study
is inversely proportional to its sample size. We further
assume that ni ¼ n 3 pi so that as the total sample size
increases, the relative proportions of sample sizes between
studies converge to fixed constants. Let ng ¼
P
i˛Sgni
denote the total sample size for Sg. With these notations,
it can be easily seen that the vector fZðbb;gÞ;Zðbb;g0Þg
converges to a bivariate normal distribution that has
a mean vector ðmðnÞg ;mðnÞg0 Þ, unit variances, and covariance
CðnÞ given by
mðnÞg ¼
X
i˛Sg
niﬃﬃﬃﬃﬃ
ng
p bi
si
¼
X
i˛SgXSg0
niﬃﬃﬃﬃﬃ
ng
p bi
s
and
CðnÞ ¼
X
i˛SgXSg0
niﬃﬃﬃﬃﬃ
ng
p ﬃﬃﬃﬃﬃﬃﬃ
ng0
p :
When all bi’s are constant ðbÞ for non-null studies, we
obtain
mðnÞg ¼
b
s
ngXg0ﬃﬃﬃﬃﬃ
ng
p ; mðnÞg0 ¼
b
s
ﬃﬃﬃﬃﬃﬃﬃ
ng0
p
; and
mðnÞg0  mðnÞg ¼
b
s
ngXg0ﬃﬃﬃﬃﬃ
ng
p
 ﬃﬃﬃﬃﬃ
ng
p ﬃﬃﬃﬃﬃﬃﬃ
ng0
p
ngXg0
 1

:
It can be seen with the Cauchy-Schwartz inequality thatﬃﬃﬃﬃﬃ
ng
p ﬃﬃﬃﬃﬃﬃﬃ
ng0
p
ngXg0
/q > 1
for some constant q, and m
ðnÞ
g0  mðnÞg therefore converges to
positive or negative infinity according to whether b is posi-
tive or negative. Now, given that Zðbb;gÞ and Zðbb;g0Þ have
finite variances and covariances but the difference in their
mean converges to infinity, it can be easily seen that for
each gsg0,
pr
 jZbb;g	 jR jZbb;g0	 j 	/0 ; and hence;
pr

argmaxgZ
bb;g	 ¼ g0	/1:
Following the above logic, we can further show that even
when the bi’s are not constant across non-null studies,
Zmaxmeta is a conservative variable selector in the sense
that for large samples, it will select only non-null studies,
but it is not guaranteed to select all of the non-null studies.
To see this, we note that, in general, for any given g, we
have m
ðnÞ
g < m
ðnÞ
gXg0
(in absolute value), and the difference
goes to infinity as the sample size increases.erican Journal of Human Genetics 90, 821–835, May 4, 2012 831
Appendix B: Discrete Local Maxima
for Subset-Based Meta-Analysis
To evaluate prðjZmaxj ¼ maxgjZðSgÞj > TÞ, the DLM method
relies on the observation that the event {jZðSgÞj > T for
some g} is contained in the union of the events {jZðSgÞj > T
and ZðSg Þ < ZðSgÞ for g neighbors of g}. Thus, by applying
Bonferroni to these unions of events, one can write
prð jZmax j ¼ maxg jZðSgÞ j> TÞR
X
g
prð jZðSgÞ j> T and
subset Sg is a localmaximum of jZðSgÞ j Þ ¼ pDLM:
Furthermore, by integrating over possible values Z of ZSg
and observing that terms corresponding to ZSg > T and
ZSg < T are equal (by symmetry), we get
pDLM ¼
X
g
ZN
T
2 pr

jZSg j< z for all neighbors g of
g jZSg ¼ z

fðzÞdz;
(Equation B1)
where fð:Þ is the standard normal density. By simplifying
and using the ‘‘separability’’ assumption, we get
~PDLM ¼
P
s˛S
ZN
T
2
YK
k¼1
prð jZs;5k j< zrZs ¼ zÞfðzÞdz
¼P
s˛S
ZN
T
2
YK
k¼1
prðlkðzÞ < Zk < ukðzÞrZs ¼ zÞfðzÞdz;
(Equation B2)
where Zs5k denotes the k
th neighbor of the current subset s
obtained by adding the kth study if it is not already
included and dropping it otherwise. The bounds lk ðzÞ
and uk ðzÞ are simple linear functions of z and meta-anal-
ysis weights (see Appendix D for details). The conditional
probabilities in the above expressions can be easily evalu-
ated with a univariate conditional normal CDF (cumula-
tive distribution function) for which the correlation is
given by the formula described in the main text. In
Appendix D, we show that the separability assumption is
conservative when the individual studies are independent.
For the two-sided meta-analysis, we apply the above
procedure to calculate the p values for the two conditional
one-sided tests,Zmax;þ and Zmax;. The steps for the calcula-
tions are analogous to those for the one-sided test except
that all of the distributions are evaluated conditionally
on the observed signs of the study-specific Z statistics.Appendix C: Discrete Local Maxima for Subtype
Analysis
Let N denote the total number of cases. Let ns be the
number of cases in a subset s of the disease subtypes and832 The American Journal of Human Genetics 90, 821–835, May 4, 2gs be the corresponding sum of genotypes for the ns
subjects. Let nk be the number of cases with the k
th subtype
of the disease. We will denote the estimated minor allele
frequency (MAF) of a SNP from all subjects by bp and denote
that from the controls by bp0. It can be shown that in the
absence of covariates and under the null hypothesis of
no association, the Z scores for ‘‘case-control’’ and ‘‘case-
complement analysis’’ for a given subset of disease
subtypes s can be asymptotically represented as
Zsz
gs  2nsbp0ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2n0spð1 pÞ
p ; where n0s ¼ ns1þ nsn0

; and
Zsz
gs  2nsbpﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2~nspð1 pÞ
p ; where ~ns ¼ nsðN  nsÞ
N
;
respectively. With the above representations, it is now easy
to relate the Z scores for neighboring subsets with the
formula
Zs5k ¼
ﬃﬃﬃﬃ
n0s
p
Zs5
ﬃﬃﬃﬃﬃ
n0k
p
Zkﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n0s5nk

15
nk
n0

52
nsnk
n0
s
for case-control analysis and with the formulae
Zsþk ¼
ﬃﬃﬃﬃ
~ns
p
Zs þ
ﬃﬃﬃﬃﬃ
~nk
p
Zkﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
~ns þ ~nk  2nkns
N
r and Zsk ¼ ﬃﬃﬃﬃ~nsp Zs  ﬃﬃﬃﬃﬃ~nkp Zkﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
~ns  ~nk þ 2
nk

nsnk
	
N
r
for case-complement analysis. Above, Zk ¼ Zfkg corre-
sponds to the Z score associated with a single disease
subtype k. These representations imply that each Zs is
a linear combination of its constituent Zk’s with positive
weights and that Zs5k’s are conditionally independent
given Zs and bp0 (or bp). It is difficult to prove the conserva-
tiveness of the separability assumption for subtype anal-
ysis unconditionally. Using the above facts, the argument
in Appendix D proves this conservativeness conditionally
given bp0 (or bp). Accordingly, one can compute bivariate
integrals in Equation B2 by conditioning on a Z score Z0
corresponding to the departure of bp0 (or bp) from the true
MAF p. However, in our simulations, we observed that
the usual DLM approximation with univariate integrals
provided adequate (i.e., conservative) p values for subtype
analysis.Appendix D: Conservativeness of the Separability
Assumption
Here, we prove the conservativeness of the ‘‘separability’’
assumption in going from Equation B1 to Equation B2,
and hence, the overall conservativeness of the DLM proce-
dure for one-sided or two-sided analysis of heterogeneous
traits by using independent studies. These arguments
also justify the conservativeness of the separability
assumption conditionally on Z0 (defined in Appendix C)
for the analysis of heterogeneous subtypes.012
Following the notation of Appendices B and C, we note
that conditional on Zs ¼ z, the events fZs5k > zg
(fZs5k > 0g for a two-sided search) are almost sure events
for large Z. Hence, it suffices to show the conservativeness
for the probabilities pr fZs5k < zckrZs ¼ zg
(pr fZs5k < z ckrZs ¼ z;Z0 ¼ z0g for subtype analysis).
Note that for both meta-analysis of heterogeneous traits
and subtype analysis, the (asymptotic) linearity of the
component Z scores implies
Zs5k ¼ ws$Zs5wk$Zk
for some positive weights ws and wk depending on sample
sizes. Hence, conditional on Zs ¼ z, we can rewrite the
events fZsþk < zg and fZsk < zg as fZk < uk ðzÞg and
fZk > lk ðzÞg, in which uk ðzÞ ¼ ðð1 wsÞzÞ=ðwkÞ and
lkðzÞ ¼ ððws  1ÞzÞ=ðwkÞ denote the lower and upper
bounds, respectively. Below, we show that given Zs ¼ z,
the K events fZs5k < zg are either independent or nega-
tively correlated to each other (conditional on Z0 ¼ z0 in
the case of subtype analysis).
Consider the pair of events fZsk < zg and fZsk0 < zg,
which correspond to Zk and Zk0 , respectively, being drop-
ped from the current subset. These events translate to
fZk > lk ðzÞg and fZk0 > lk0 ðzÞg, which are negatively corre-
lated events (because Zk and Zk0 are part of the positively
weighted linear combination Zs, which is fixed at z). Simi-
larly, the events fZsþk < zg and fZsþk0 < zg, corresponding
to Zk and Zk0 , respectively, being added to the current
subset translate to fZk < uk ðzÞg and fZk0 < uk0 ðzÞg, respec-
tively. These are independent given that the weighted sum
Zs ¼ z does not involve Zk and Zk0 . Finally, the events
fZsþk < zg and fZsk0 < zg translate to fZk < uk ðzÞg and
fZk0 > lk0 ðzÞg. Again, these are independent given that
Zs ¼ z does not constrain Zk.
Thus, in each case, either independent or negatively
correlated events are being separated as a product, which
implies that each probability term is being approximated
conservatively.Supplemental Data
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